[Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study]
- PMID: 10554512
- DOI: 10.1007/BF03044951
[Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study]
Abstract
Background: The regular i.v.-therapy of adults with cystic fibrosis (CF) on an in-patient basis is regarded as expensive. Home treatment is supposed to be cheaper. During a prospective controlled study to compare in-patient treatment (SIT) with home i.v.-treatment (HIT) in regard to clinical, psychosocial and economic parameters, delivered health services and costs in the German setting were evaluated in a comparable manner.
Patients and methods: During the study period 4/95 to 9/96 45 patients with altogether 56 hospital and 40 home i.v.-courses of approximately 14 days were included in the study. Principal instruments to record the resource consumption were documentation sheets kept by the medical staff and the patients. In addition, pharmacy accounts in HIT and patient records and hospital controlling data in SIT were used.
Results: The average costs of a course were 14,038 DM for HIT and 18,702 DM for SIT. Striking are the large differences in medication costs. Two main reasons could be identified for the cost difference: 1, the use of a mobile infusion system in HIT and 2, the much higher prices of pharmaceuticals in the ambulatory care sector compared to the hospital sector, where extremely high profits of the home care service firms or the pharmacy can be supposed. The social costs of HIT (when antibiotics are valued to opportunity costs) are estimated at less than 10,500 DM. From a societal perspective HIT is preferable, from the perspective of the statutory health insurance funds hospital therapy is preferable.
Conclusions: 1. The widely accepted hypothesis that ambulatory care is cheaper than hospital care is--at least in the German setting--not a-priori true. 2. In the treatment of CF patients incentive failures exist which induce unnecessary and avoidable hospital stays if the perspective of the statutory sickness funds is dominant. 3. Changes in system conditions as e.g. the permission of mail-order pharmacies might help to implement a more rational allocation of resources.
Similar articles
-
Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.Pharmacoeconomics. 2003;21(14):1001-24. doi: 10.2165/00019053-200321140-00002. Pharmacoeconomics. 2003. PMID: 13129414 Review.
-
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.Pharmacoeconomics. 2012 Sep 1;30(9):763-77. doi: 10.2165/11588870-000000000-00000. Pharmacoeconomics. 2012. PMID: 22690685
-
Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.Int J Technol Assess Health Care. 2006 Fall;22(4):525-31. doi: 10.1017/S0266462306051476. Int J Technol Assess Health Care. 2006. PMID: 16984688
-
[Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment].Med Klin (Munich). 1997 Oct 15;92(10):626-9. doi: 10.1007/BF03044791. Med Klin (Munich). 1997. PMID: 9446013 German.
-
Costs and benefits of health information technology.Evid Rep Technol Assess (Full Rep). 2006 Apr;(132):1-71. doi: 10.23970/ahrqepcerta132. Evid Rep Technol Assess (Full Rep). 2006. PMID: 17627328 Free PMC article. Review.
Cited by
-
[When is expensive pharmacotherapy good value for the money?].Internist (Berl). 2004 Oct;45(10):1189-95. doi: 10.1007/s00108-004-1238-z. Internist (Berl). 2004. PMID: 15526176 Review. German.
-
Psychological interventions for individuals with cystic fibrosis and their families.Cochrane Database Syst Rev. 2014 Jun 18;2014(6):CD003148. doi: 10.1002/14651858.CD003148.pub3. Cochrane Database Syst Rev. 2014. PMID: 24941199 Free PMC article.
-
Quantifying cost savings from outpatient parenteral antimicrobial therapy programme: a systematic review and meta-analysis.JAC Antimicrob Resist. 2025 Apr 8;7(2):dlaf049. doi: 10.1093/jacamr/dlaf049. eCollection 2025 Apr. JAC Antimicrob Resist. 2025. PMID: 40201538 Free PMC article. Review.
-
Staff costs of hospital-based outpatient care of patients with cystic fibrosis.Health Econ Rev. 2011 Aug 3;1(1):10. doi: 10.1186/2191-1991-1-10. Health Econ Rev. 2011. PMID: 22828269 Free PMC article.
-
Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.Pharmacoeconomics. 2003;21(14):1001-24. doi: 10.2165/00019053-200321140-00002. Pharmacoeconomics. 2003. PMID: 13129414 Review.